CD25hi Treg depleted DLI
/ Dana-Farber Cancer Institute
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
September 20, 2025
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
(clinicaltrials.gov)
- P1 | N=25 | Active, not recruiting | Sponsor: Dana-Farber Cancer Institute | Trial completion date: Jul 2025 ➔ Dec 2026
Trial completion date • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • IL2RA • ISG20
July 31, 2024
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
(clinicaltrials.gov)
- P1 | N=25 | Active, not recruiting | Sponsor: Dana-Farber Cancer Institute | Trial completion date: Jul 2024 ➔ Jul 2025
Trial completion date • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • IL2RA • ISG20
June 11, 2024
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
(clinicaltrials.gov)
- P1 | N=25 | Active, not recruiting | Sponsor: Dana-Farber Cancer Institute | Recruiting ➔ Active, not recruiting | Trial completion date: May 2025 ➔ Jul 2024
Enrollment closed • Trial completion date • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • IL2RA • ISG20
May 23, 2023
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
(clinicaltrials.gov)
- P1 | N=25 | Recruiting | Sponsor: Dana-Farber Cancer Institute | Trial completion date: May 2024 ➔ May 2025 | Trial primary completion date: May 2023 ➔ May 2024
Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • IL2RA • ISG20
May 17, 2022
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
(clinicaltrials.gov)
- P1 | N=25 | Recruiting | Sponsor: Dana-Farber Cancer Institute | Trial primary completion date: Apr 2022 ➔ May 2023
Trial primary completion date • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • IL2RA
1 to 5
Of
5
Go to page
1